Monopar Therapeutics Q4 net loss narrows on lower R&D costs

Reuters

Yesterday

<a href="https://laohu8.com/S/MNPR">Monopar Therapeutics</a> Q4 net loss narrows on lower R&D costs

Overview

US biopharmaceutical firm's Q4 net loss narrowed yr/yr
Lower R&D expenses reflect absence of one-time ALXN1840 in-licensing costs incurred in 2024

Outlook

Monopar plans to submit NDA for ALXN1840 to FDA in mid-2026
Company expects current funds to support operations through at least Dec 31, 2027

Result Drivers

LOWER R&D EXPENSES - Q4 R&D expenses fell due to absence of one-time ALXN1840 in-licensing costs from prior yr
HIGHER G&A EXPENSES - Q4 G&A expenses rose due to increased personnel costs, stock-based compensation, bonuses, and higher patent legal fees

Company press release: ID:nGNX9rJKMz

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Net Income		-$5.2 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Monopar Therapeutics Inc is $112.00, about 105.3% above its March 26 closing price of $54.56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622046871"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622046871\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622046871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 01:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622046871","market":"nz","top_or_hot":-1,"title":"Monopar Therapeutics Q4 net loss narrows on lower R&D costs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/MNPR\">Monopar Therapeutics</a> Q4 net loss narrows on lower R&amp;D costs</title></head><body><p><span>Overview</span></p><ul><li><p>US biopharmaceutical firm's Q4 net loss narrowed yr/yr</p></li><li><p>Lower R&amp;D expenses reflect absence of one-time ALXN1840 in-licensing costs incurred in 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Monopar plans to submit NDA for ALXN1840 to FDA in mid-2026</p></li><li><p>Company expects current funds to support operations through at least Dec 31, 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER R&amp;D EXPENSES - Q4 R&amp;D expenses fell due to absence of one-time ALXN1840 in-licensing costs from prior yr</p></li><li><p>HIGHER G&amp;A EXPENSES - Q4 G&amp;A expenses rose due to increased personnel costs, stock-based compensation, bonuses, and higher patent legal fees</p></li></ul><p>Company press release: <span>ID:nGNX9rJKMz</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$5.2 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Monopar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $112.00, about 105.3% above its March 26 closing price of $54.56</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monopar Therapeutics Q4 net loss narrows on lower R&D costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonopar Therapeutics Q4 net loss narrows on lower R&D costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 01:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/MNPR\">Monopar Therapeutics</a> Q4 net loss narrows on lower R&amp;D costs</title></head><body><p><span>Overview</span></p><ul><li><p>US biopharmaceutical firm's Q4 net loss narrowed yr/yr</p></li><li><p>Lower R&amp;D expenses reflect absence of one-time ALXN1840 in-licensing costs incurred in 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Monopar plans to submit NDA for ALXN1840 to FDA in mid-2026</p></li><li><p>Company expects current funds to support operations through at least Dec 31, 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER R&amp;D EXPENSES - Q4 R&amp;D expenses fell due to absence of one-time ALXN1840 in-licensing costs from prior yr</p></li><li><p>HIGHER G&amp;A EXPENSES - Q4 G&amp;A expenses rose due to increased personnel costs, stock-based compensation, bonuses, and higher patent legal fees</p></li></ul><p>Company press release: <span>ID:nGNX9rJKMz</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$5.2 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Monopar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $112.00, about 105.3% above its March 26 closing price of $54.56</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL1N40F0RW:1","article_id":"2622046871","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622046871","pubTimestamp":1774631916,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Monopar Therapeutics Q4 net loss narrows on lower R&D costsOverviewUS biopharmaceutical firm's Q4 net loss narrowed yr/yrLower R&D expenses reflect absence of one-time ALXN1840 in-licensing costs incu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MNPR":"Monopar Therapeutics"},"translate_title":"Monopar Therapeutics第四季度净亏损因研发成本降低而收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNPR":0.9},"content_text":"Monopar Therapeutics Q4 net loss narrows on lower R&D costsOverviewUS biopharmaceutical firm's Q4 net loss narrowed yr/yrLower R&D expenses reflect absence of one-time ALXN1840 in-licensing costs incurred in 2024OutlookMonopar plans to submit NDA for ALXN1840 to FDA in mid-2026Company expects current funds to support operations through at least Dec 31, 2027Result DriversLOWER R&D EXPENSES - Q4 R&D expenses fell due to absence of one-time ALXN1840 in-licensing costs from prior yrHIGHER G&A EXPENSES - Q4 G&A expenses rose due to increased personnel costs, stock-based compensation, bonuses, and higher patent legal feesCompany press release: ID:nGNX9rJKMzKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Net Income-$5.2 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Monopar Therapeutics Inc is $112.00, about 105.3% above its March 26 closing price of $54.56For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}